Overview

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

Status:
Recruiting

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

Summary

A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.

Phase:

Phase 2

Details

Lead Sponsor:

KalVista Pharmaceuticals, Ltd.